2026-08-29T14:04:52Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/66992024-09-27T10:02:40Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605
Repisalud
author
Cirauqui, Cristina
author
Benito-Villalvilla, Cristina
author
Sanchez-Ramon, Silvia
author
Sirvent, Sofia
author
Diez-Rivero, Carmen M.
author
Conejero, Laura
author
Brandi, Paola
author
Hernandez-Cillero, Lourdes
author
Ochoa, Juliana Lucia
author
Perez-Villamil, Beatriz
author
Sancho, David
author
Luis Subiza, Jose
author
Palomares, Óscar
funder
Ministerio de Economía, Industria y Competitividad (España)
funder
Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
funder
European Respiratory Society
2018-11-22T08:10:55Z
2018-11-22T08:10:55Z
2018
Eur J Immunol. 2018; 48(1):180-193
10.1002/eji.201747024
1521-4141
0014-2980
European Journal of Immunology
28799230
http://hdl.handle.net/20.500.12105/6699
Recurrent respiratory tract infections (RRTIs) are the first leading cause of community-and nosocomial-acquired infections. Antibiotics remain the mainstay of treatment, enhancing the potential to develop antibiotic resistances. Therefore, the development of new alternative approaches to prevent and treat RRTIs is highly demanded. Daily sublingual administration of the whole heat-inactivated polybacterial preparation (PBP) MV130 significantly reduced the rate of respiratory infections in RRTIs patients, however, the immunological mechanisms of action remain unknown. Herein, we study the capacity of MV130 to immunomodulate the function of human dendritic cells (DCs) as a potential mechanism that contribute to the clinical benefits. We demonstrate that DCs from RRTIs patients and healthy controls display similar ex vivo immunological responses to MV130. By combining systems biology and functional immunological approaches we show that MV130 promotes the generation of Th1/Th17 responses via receptor-interacting serine/threonine-protein kinase-2 (RIPK2)-and myeloid-differentiation primary-response gene88 (MyD88)-mediated signalling pathways under the control of IL-10. In vivo BALB/c mice sublingually immunized with MV130 display potent systemic Th1/Th17 and IL-10 responses against related and unrelated antigens. We elucidate immunological mechanisms underlying the potential way of action of MV130, which might help to design alternative treatments in other clinical conditions with high risk of recurrent infections.
eng
Dendritic cells (DCs)
IL-10-producing T cells
Recurrent respiratory tract infections (RRTIs)
Th1/Th17 cells
Whole heat-inactivated polybacterial vaccines
Human dendritic cells activated with MV130 induce Th1, Th17 and IL-10 responses via RIPK2 and MyD88 signalling pathways
journal article
URL
https://repisalud.isciii.es/bitstreams/8a6d661d-37a3-4145-a17b-d8104f43d72e/download
File
MD5
98b1e8db81d00bfdbc046bdd4b9f908d
3614915
application/pdf
HumanDendriticCellsActivated_2018.pdf
URL
https://repisalud.isciii.es/bitstreams/d35acea4-dae3-4285-ac74-9d1c7c1ceced/download
File
MD5
ba17e83b0d8278d32c85d3b6e86a40a9
212054
application/pdf
HumanDendriticCellsActivated_2018-s1-s2.pdf
URL
https://repisalud.isciii.es/bitstreams/1c4781cc-a831-4950-89b9-12599b7ebeff/download
File
MD5
2ecffd8ff672e65b0b018deec1eee2f6
61701
text/plain
HumanDendriticCellsActivated_2018.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/e182e629-f0f6-4d01-8e92-2e0d91e26684/download
File
MD5
00535691f0acfc0a2aff44158a27132a
1349
text/plain
HumanDendriticCellsActivated_2018-s1-s2.pdf.txt